Ann: Positive results received for Emyrias MDMA-inspired program, page-30

very difficult as valuation ranges the gauntlet. 250m can be on successful phase 2 (especially with a safety profile like we have) and yet here we are at phase 3 at 70m. look at IHLs run to 700m and back down. I always thought EMD was a better value proposition. why? (retail pumping is not the investment I'm here for. I'm after that 5B validated data).

I also see that Ihl chief med jumped ship on the pump (hey who wouldn't take the money and run)

now we actually have x2 phase 2 ticked off. and we don't pump an Ann every second moment. EMD tightly held quiet company ticking goals.

our RWD is backed using a system that the FDA has confidence in. we also have the first registered medical device to capture data by the tga.

I'm still expecting not many to yet understand the leverage and compounding effect RWD will have to inform given it is still new in the medical setting.

oh and hey I'm expecting we will soon cross over another 1000 people coming through the RWD pipeline.